$10.96
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Coeptis Therapeutics Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Wexford, Pennsylvania and currently employs 4 full-time employees. The company went IPO on 2020-12-17. Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The firm is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its segments are Biotechnology and Technology. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Country

US

CEO

Mr. David Mehalick

IPO date

2020

Employees

4

ISIN

US98878K1088

Key stats

Open

$11.75

Volume

164.71K

Market cap

$478.83M

Prev. close

$10.92

Impl / hst vl

-

Open interest

$0.00

$10.71

Day’s Range

$11.75

$8.00

52W Range

$16.74

Valuation

55
Valuation score
Fairly Valued
P/E
-
P/S
-
P/B
-
Current ratio
3.25
Debt / Equity
-0.29
ROE
-99.73%
Gross margin
60.31%
Income growth
148.22%
FCF growth
4.21

Analysts estimates

Consensus rating
Hold

The average rating from top 3 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy

Earnings

Q1 ‘26 revenue
$113.80K
Q1 ‘26 net income
-$3.92M
Revenue
Net income
Previous EPS
-
Estimate EPS
$0.00
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply